| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1986 | Epz005687n | Inactive isomer of EPZ005687 and can be used as the negative control for EPZ005687 |
|
| DCC1987 | Epz028862 | Novel selective SMYD3 inhibitor |
|
| DCC1988 | Epz032597 | Novel selective SMYD2 inhibitor |
|
| DCC1989 | Epz033294 | Novel SMYD2 inhibitor |
|
| DCC1990 | Er Degrader 40 | Novel Oral Selective Estrogen Receptor Degrader with Highly Improved Antitumor Effect and Favorable Druggability |
|
| DCC1991 | Er-119884 | Selective squalene synthase (SQS) inhibitor |
|
| DCC1992 | Er-38925 | Retinoic acid receptor (RAR) subtype α-selective agonist |
|
| DCC1993 | Erap1 -in-1 | Novel Selective ERAP1 Inhibitor |
|
| DCC1994 | Erap1-in-2 | Novel competitive inhibitor of ERAP1 aminopeptidase activity |
|
| DCC1995 | Erbb-in-1 | Novel ErbB type I receptor tyrosine kinase inhibitor for the treatment of hyperproliferative diseases |
|
| DCC1996 | Ercc1-xpf-in-4 | Novel potent inhibitor of ERCC1-XPF activity, targeting DNA repair in tumor cells |
|
| DCC1997 | Ergotamine | Natural Nsp15 inhibitor against SARS-COV2 |
|
| DCC1998 | Erioflorin | Novel ATP-competitive Selective c-Jun N-terminal kinase (JNK) inhibitor |
|
| DCC1999 | Eritoran | Analogue of the lipid A portion of the endotoxin lipopolysaccharide (LPS) with potential immunomodulating activity, binding to the Toll-like receptor (TLR)/CD14/MD2 receptor complex, inhibiting the activation of the receptor complex by LPS |
|
| DCC2000 | Erk Inhibitor Ii, Negative Control | Negative control for ERK Inhibitor II AOB6420 |
|
| DCC2001 | Erk-cliptac | Novel degrader of ERK1/2, eliciting downregulation of phospho-ERK1/2 signal. |
|
| DCC2002 | Errα Degrader-1 | Novel PROTAC Estrogen-related Receptor α (ERRα) Degrader |
|
| DCC2003 | Erso-dfp | Novel Activator of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer |
|
| DCC2004 | Erß Nir Probe P5 | The first ERβ-targeted near-infrared (NIR) inherently fluorescent probe, showing the advantages of high ERβ selectivity, good optical properties, and excellent ERβ imaging capability in living cells |
|
| DCC2005 | Ertapenem Disodium | Carbapenem antibiotic, inhibiting cross-linking of the peptidoglycan layer of bacterial cell walls by blocking penicillin-binding proteins (PBPs) |
|
| DCC2006 | Erthermac | Novel thermosensitive fluorescent dye, visualizing thermogenesis in stimulated single-cell brown adipocytes |
|
| DCC2007 | Er-thermo-yellow | The First Fluorescent Probe for Targeted Visualization of Temperature at the Endoplasmic Reticulum #222222; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0.17px; text-align: start; text-in |
|
| DCC2008 | Erw1041e | Novel potent inhibitor of recombinant human and mouse Transglutaminase enzyme activity, mainly TG2 and the close related enzyme TG1 |
|
| DCC2009 | Erythrocentaurin | Anti-HBV agent, showing activities on HepG 2.2.15 cell line in vitro |
|
| DCC2010 | Erythro-di-o-benzyl Droxidopa Hcl | Precursor of adrenaline, suppressing the locomotor stimulation by MAO inhibitor |
|
| DCC2011 | Erythromycin Ethylsuccinate | Broad-spectrum, topical macrolide antibiotic, diffusing through the bacterial cell membrane and reversibly binding to the 50S subunit of the bacterial ribosome |
|
| DCC2012 | escaline Hydrochloride | Serotonin 5-HT2A Agonist |
|
| DCC2013 | Est64454 | Novel Highly Soluble σ1 Receptor Antagonist for Pain Management |
|
| DCC2014 | Estetrol | Selective estrogen receptor modulator (SERM), exhibiting estrogen agonism in certain tissues and estrogen antagonism in others |
|
| DCC2015 | Cgs-27023a | Non-Peptidic, potent, and orally active stromelysin inhibitor, blocking cartilage degradation |
|
